EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1 /2‐mutated cancer

Shuyi Wu iD, Xuanjie Yao, Weiwei Sun, Kaitao Jiang, Jie Hao

Genes, Chromosomes and Cancer · 2024

DOI: 10.1002/gcc.23243 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, Chromosomes and Cancer, 2024. Verfasst von Shuyi Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhejiang Chinese Medicine University, HangZhou, China. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 120 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer susceptibility 1/2 (BRCA1/2) genes play a crucial role in DNA damage repair, yet mutations in these genes increase the susceptibility to tumorigenesis. Exploiting the synthetic lethality mechanism between BRCA1/2 mutations and poly(ADP‐ribose) polymerase (PARP) inhibition has led to the development and clinical approval of PARP inhibitor (PARPi), representing a milestone in targeted therapy for BRCA1/2 mutant tumors. This approach has paved the way for leveraging synthetic lethality in tumor treatment strategies. Despite the initial success of PARPis, resistance to these agents diminishes their efficacy in BRCA1/2‐mutant tumors. Investigations into PARPi resistance have identified replication fork stability and homologous recombination repair as key factors sensitive to PARPis. Additionally, studies suggest that replication gaps may also confer sensitivity to PARPis. Moreover, emerging evidence indicates a correlation between PARPi resistance and cisplatin resistance, suggesting a potential overlap in the mechanisms underlying resistance to both agents. Given these findings, it is imperative to explore the interplay between replication gaps and PARPi resistance, particularly in the context of platinum resistance. Understanding the impact of replication gaps on PARPi resistance may offer insights into novel therapeutic strategies to overcome resistance mechanisms and enhance the efficacy of targeted therapies in BRCA1/2‐mutant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmBRCA2 ProteinBRCA1 ProteinMutationHumansFemaleBreast NeoplasmsAntineoplastic AgentsNeoplasms

Stichwörter der Autor:innen

BRCA1/2 genePARPihomologous recombinationreplication gaps

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • School of Life Sciences, Zhejiang Chinese Medicine University, HangZhou, China.
  • The Fourth Clinical Medical College, Zhejiang Chinese Medicine University, HangZhou, China.

ORCID-Profile: Shuyi Wu

Zitieren

APA

Wu, S., Yao, X., Sun, W., Jiang, K., & Hao, J. (2024). Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1 /2‐mutated cancer. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23243

Vancouver

Wu S, Yao X, Sun W, Jiang K, Hao J. Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1 /2‐mutated cancer. Genes, Chromosomes and Cancer. 2024. doi:10.1002/gcc.23243

BibTeX
@article{Wu2024,
  author = {Wu, Shuyi and Yao, Xuanjie and Sun, Weiwei and Jiang, Kaitao and Hao, Jie},
  title = {Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1 /2‐mutated cancer},
  journal = {Genes, Chromosomes and Cancer},
  year = {2024},
  doi = {10.1002/gcc.23243}
}
Kostenlos starten →